||It has been suggested that this article be merged into Lupin Limited. (Discuss) Proposed since February 2014.|
|Headquarters||Baltimore, Maryland, Baltimore, USA|
|Products||Pharmaceuticals, branded and generic drugs, biotechnology, Advanced Drug Delivery Systems, New Chemical Entity Research, vaccines, Over-the-Counter drugs|
|Revenue||$803 million USD (FY 2014)|
Lupin Pharmaceuticals, Inc. (LPI), the U.S. subsidiary of Indian pharma major, Lupin Limited is headquartered in Baltimore, Maryland. The company has a presence in the branded as well as the generics markets, and as of 2014, it remains one of the few global generics pharma majors with a substantial branded play within the country. With revenues of over $803 million in FY 2014, the company is the 5th largest and the fastest growing generics player in the US (5.4% market share by prescriptions, IMS Health). Lupin's US brands business contributed 10% of total US sales whereas the generics business contributed 90% during FY 2014.
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003. LPI’s strength in the generics market is best characterized by its ability to achieve leading market shares in even the most competitive market scenarios. As of March 2014, 31 of the 63 generic products marketed by LPI in the US ranked No. 1 by market share and 53 of the 63 are in the top 3 by Market share (IMS Health). The US Generics business continued its impressive growth story in FY 2014, recording revenues of USD 723 million, an increase of 32% over last year. In FY 2014, they launched 19 new products, including the successful commercialization of generic versions of Zymaxid®, Trizivir® and Cymbalta®.
Lupin Pharmaceuticals, Inc. (LPI) is committed to developing a branded pharmaceutical presence for pediatric practice in the US market. LPI entered the branded business with Suprax®, an anti-infective product in pediatric. Suprax® is now available in tablets and suspension formulations. Lupin Pharmaceuticals, Inc., has an exclusive license in the United States to use the Suprax® trademark. LPI continues to expand its Suprax® branded franchise with the launch of a capsule dosage form in FY 2014, building on the FY 2013 addition of Suprax® chewable tablets. The total Suprax® family of products continues to grow and remains the foundation of the company’s US branded business.
Further expanding their branded portfolio, in September 2009, LPI acquired the US rights for Antara (Fenofibrate Capsules 43mg and 130mg). Antara® has a strong brand equity with primary care physicians treating patients for high LDL-C, Total-C, triglycerides, Apo-B and low HDL-C. In FY 2014, LPI introduced the Antara® 90mg capsules. LPI has maintained 70% market share of the Fenofibrate 130mg market with their brand and authorized generic products.
In FY 2014, the Company added two new products to its portfolio in order to enhance and extend its US brands business for the future. In August FY 2013, they acquired exclusive rights to promote, distribute and market Alinia®(nitazoxanide) for oral suspension in the US. In September 2013, LPI also signed a strategic co-promotion agreement for exclusive rights to promote Locoid® Lotion (hydrocortisone butyrate 0.1%) to the Pediatric community in the US.
- New Leadership team at Lupin from Sept. 2013
|This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it.|